Spruce Biosciences Signals Commercial Shift with Key Hire for Rare Disease Drug

SOUTH SAN FRANCISCO, Calif. – June 22, 2026 – In the high-stakes world of biotechnology, personnel moves are often telegraphed signals of a company's next strategic chapter. For Spruce Biosciences, a late-stage biopharmaceutical firm, the appointment of Agnieszka “AJ” Jurecka, M.D., Ph.D., MPH, as its new Vice President of Medical Affairs is less a simple announcement and more a declaration of intent. The company is preparing for war—a commercial war against a devastating disease and the market complexities that come with fighting it.

Spruce is on the cusp of a potential U.S. approval for its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), a treatment for the rare and fatal pediatric neurodegenerative disorder, Sanfilippo Syndrome Type B. With no currently approved therapies, a successful launch would be a landmark medical achievement and a financial windfall. But bringing a first-of-its-kind orphan drug to market is a gauntlet. The hire of Dr. Jurecka is Spruce’s strategic play to ensure it has the right general to lead the charge.

A Veteran for a Pivotal Moment

Dr. Jurecka is not a typical executive hire; she is a specialist, a rare disease veteran whose career reads like a roadmap for developing and commercializing the very type of therapy Spruce has staked its future on. Her more than 20-year career is a deep dive into lysosomal storage disorders and enzyme replacement therapies (ERTs)—the exact scientific and clinical space TA-ERT occupies.

Her resume is a tour of the most prominent players in the rare disease field. At Ultragenyx, she was a Senior Medical Director supporting the MPS VII enzyme replacement therapy program. At Shire, she worked on programs for MPS II, including complex intrathecal ERT delivery. Her experience extends to BioMarin, Synageva, and most recently as Chief Medical Officer for a gene therapy startup. This isn't just broad experience; it's hyper-specific expertise in the precise challenges Spruce will face. She has navigated the journey from pre-IND to late-stage and Phase IV studies, engaging with the FDA and EMA along the way.

“She is a rare combination of practicing physician, scientist, and biopharmaceutical leader, with directly relevant enzyme replacement therapy and lysosomal storage disorder experience,” said Kirk Ways, M.D., Ph.D., Chief Medical Officer of Spruce Biosciences, in the official announcement. This statement, while standard corporate praise, undersells the strategic importance. In Dr. Jurecka, Spruce gains a leader who has already built the playbook for launching a complex ERT, from establishing disease awareness in a medical community unfamiliar with the condition to building the durable relationships with Key Opinion Leaders (KOLs) who will be crucial for adoption.

The High Stakes of Sanfilippo Syndrome

To understand the significance of this move, one must understand the gravity of Sanfilippo Syndrome Type B (MPS IIIB). It is a cruel disease, a lysosomal storage disorder where a missing enzyme, NAGLU, causes a toxic buildup of heparan sulfate in the body’s cells, most devastatingly in the brain. Children with the condition experience progressive and severe neurological decline, including loss of speech, cognitive function, and mobility. It is a fatal diagnosis with no FDA-approved treatment.

Spruce's TA-ERT aims to be the first disease-modifying therapy by replacing the missing enzyme. The potential impact is profound, and regulatory bodies have taken notice. The therapy has been granted a suite of designations from the FDA—Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug—each one a signal of the agency's recognition of the high unmet need and the drug's potential. These designations don't guarantee approval, but they clear a path for expedited review and provide powerful incentives, such as a potential Priority Review Voucher that can be sold for a significant sum.

“Sanfilippo Syndrome Type B is a devastating disease, and TA-ERT has the potential to be the first disease-modifying therapy for the children and families affected by it,” Dr. Jurecka stated. Her words reflect the core mission that drives the rare disease sector, but they also underscore the commercial opportunity. For a company like Spruce, whose fate is almost entirely tied to this single asset, successfully bringing it to market is everything.

Navigating the Commercial Gauntlet

The transition from a clinical-stage to a commercial-stage entity is one of the most perilous in biotech. This is especially true in the orphan drug market. While the lack of competition is an advantage, the challenges are unique and formidable. The patient population is small and difficult to identify. The price tag for such therapies is invariably high, attracting intense scrutiny from payers and health systems. This is where Dr. Jurecka’s role becomes paramount.

Her mandate as VP of Medical Affairs is to build the scientific and medical foundation for the commercial launch. This involves educating physicians about a disease they may have never seen, presenting the complex clinical data in a compelling way, and preparing the market to understand the value proposition of a high-cost, high-impact therapy. It is a role that sits at the intersection of science, medicine, and business strategy.

Spruce is arming her for this task. The company's financial footing appears solid, with reports indicating it holds more cash than debt. The inducement award granted to Dr. Jurecka—3,800 restricted stock units—is a standard but important signal, aligning her personal success directly with the company's long-term performance. In a volatile market, where Spruce's stock (Nasdaq: SPRB) has seen dramatic swings, such strategic moves are designed to build investor confidence and demonstrate that a clear plan for value creation is in place. This appointment is a clear message to the market that Spruce is not just hoping for approval; it is actively building the sophisticated commercial and medical infrastructure required to capitalize on it.